Drug development in many areas of immunology is thriving, with companies expanding their pipelines in cardiometabolic, auto-immune or kidney diseases. Various rare but devastating conditions are also the focus of the industry, with a number of orphan drugs rapidly progressing through clinical development.
tranScrip’s expertise covers small molecules as well as monoclonal antibodies, cell therapy, antisense oligo-nucleotides and gene therapy. We are helping our clients seize opportunities and meet their development goals by challenging the current clinical and regulatory paradigms.
We provide strategic expertise, therapeutic experience and operational excellence across the entire product lifecycle.
Our experienced physicians and scientists, together with our regulatory, clinical and commercial experts can support you to maximise the value of your products. Whatever your project requires, we have the expertise to meet your needs.
